BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 17875725)

  • 21. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
    Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
    Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
    Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
    J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
    Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
    Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Herman EH; Zhang J; Chadwick DP; Ferrans VJ
    Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
    Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
    Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase 2β Induces DNA Breaks To Regulate Human Papillomavirus Replication.
    Kaminski P; Hong S; Kono T; Hoover P; Laimins L
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
    Jirkovská A; Karabanovich G; Kubeš J; Skalická V; Melnikova I; Korábečný J; Kučera T; Jirkovský E; Nováková L; Bavlovič Piskáčková H; Škoda J; Štěrba M; Austin CA; Šimůnek T; Roh J
    J Med Chem; 2021 Apr; 64(7):3997-4019. PubMed ID: 33750129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
    Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
    Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
    Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.